In a news release, Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced it garnered OxC-beta™ orders from two Asian companies.
One is Top Feed, a commercial mill in Thailand that produces poultry and swine feeds, and Avivagen's first customer in that country, in 2018. Since then, Top Feed increased the frequency of its orders, to every month from every six months, and for the last four months it ordered 50 kilograms of OxC-beta instead of 25. "This significant increase in size and frequency of Top Feed's orders is typical of the product use trajectory seen with several of our customers, and confirms our strategy of allowing new customers to test small amounts at first, leading to significant increases in use and frequency thereafter," the company noted.
Avivagen's other buyer is Fwusow in Taiwan, a new customer. The company produces and sells food for livestock as well as companion animals, including dogs, cats and ornamental fish. Its dog food is the No. 1 selling brand in Taiwan.
With the OxC-beta it buys, Fwusow intends to use it in a new dog food line it will develop and sell, the packaging of which will denote, "Powered by OxC-beta." These new products and the branding will raise awareness about Avivagen's product and, also, "facilitate the introduction of OxC-beta into Fwusow's lines of integrated and commercial livestock feeds in the future," the release noted.
"Both the success to date with Top Feed in Thailand and the plans and potential for OxC-beta use in the Taiwanese companion animal and livestock markets through Fwusow are a very strong reflection of the overall increase in demand, expanding application consideration and growing market opportunity for OxC-beta across Asia," Avivagen CEO Kym Anthony said in the release.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
